VINCOBODIES: The next generation in immunotherapy
We are advancing a new class of multi-specific cancer therapies built on our proprietary VINCOBODY® platform, engineered to deliver the power of combination immuno-oncology (IO) and multi-payload antibody drug conjugates (ADCs) without the toxicities and limitations of conventional approaches.
VINCOBODIES are compact, modular, high-potency VHH antibody fragments designed to overcome the size, complexity, and toxicity challenges of conventional immunotherapies. They deliver multi-target potency and multi-payload flexibility with the safety profile needed to unlock new IO combinations — all in a simple, subcutaneous dose.
Evolutionary VINCOBODIES lead to revolutionary medicines
With the ability to simultaneously target multiple immune pathways and penetrate tumors deeply at low doses, VINCOBODIES target solid tumors where current immunotherapies fall short.
VINCOBODIES avoid Fc-mediated T-reg depletion, reducing immune-related adverse events that force up to 70% of patients off current IO regimens. Our lead program, VCR-036, is designed to bring combination PD-1 + CTLA-4 efficacy to colorectal cancer patients without the dose-limiting toxicities that keep most patients from benefiting.
The Vicero Pipeline
Our VINCOBODY platform powers a growing pipeline of multi-specific immunotherapies and ADCs.
Our lead program, VCR-036 — a bi-specific VINCOBODY — combines neutralization of PD-1 and CTLA-4 receptors on a single scaffold, delivering best-in-class potency and safety in preclinical studies.
